$29.66-3.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$25.1M | -$14.2M | -77.17% |
| Profit per share | -$0.54 | -$0.52 | -3.85% |
| Free Cash Flow | -$20.8M | -$9.9M | -109.28% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Alto Neuroscience, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Alto Neuroscience (NYSE: ANRO) is a clinical-stage biopharmaceutical company on a mission to transform the treatment of mental health conditions through a deeper understanding of the brain. Leveraging its proprietary Precision Psychiatry Platform™, Alto is advancing a broad pipeline of novel medicines for depression, schizophrenia, and other neuropsychiatric disorders. The Company’s lead program, ALTO-207, is in late-stage clinical development for treatment-resistant depression.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Alto Neuroscience, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.